WallStSmart

Agilent Technologies Inc (A)vsCastle Biosciences Inc (CSTL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 2028% more annual revenue ($7.23B vs $339.92M). A leads profitability with a 19.6% profit margin vs -3.8%. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

CSTL

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-73.0%)

Margin of Safety

-73.0%

Fair Value

$74.53

Current Price

$126.49

$51.96 premium

UndervaluedFair: $74.53Overvalued
CSTLUndervalued (+58.2%)

Margin of Safety

+58.2%

Fair Value

$77.42

Current Price

$21.38

$56.04 discount

UndervaluedFair: $77.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

CSTL3 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
26.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

CSTL4 concerns · Avg: 2.5/10
Market CapQuality
$627.83M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Revenue GrowthGrowth
-4.9%2/10

Revenue declined 4.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : CSTL

The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : CSTL

The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

A profiles as a mature stock while CSTL is a turnaround play — different risk/reward profiles.

A carries more volatility with a beta of 1.26 — expect wider price swings.

A is growing revenue faster at 10.0% — sustainability is the question.

A generates stronger free cash flow (184M), providing more financial flexibility.

Bottom Line

A scores higher overall (71/100 vs 31/100), backed by strong 19.6% margins. CSTL offers better value entry with a 58.2% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Castle Biosciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Castle Biosciences Inc. is a leading diagnostics company dedicated to improving patient care through cutting-edge gene-expression profiling tests, specifically in the realm of skin cancer, with its flagship product, DecisionDx®-Melanoma. This innovative solution provides crucial insights into patient risk stratification, thus facilitating informed treatment decisions in melanoma management. With a steadfast commitment to precision medicine and a robust research and development framework, Castle Biosciences is strategically positioned to expand its portfolio and address pivotal clinical needs. By focusing on the complexities of oncology, the company aims to enhance clinical outcomes while driving significant value for shareholders.

Visit Website →

Want to dig deeper into these stocks?